Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
28
CRSP Quote, Financials, Valuation and Earnings
Last price:
$40.74
Seasonality move
:
16.92%
Day range:
$39.41 - $41.02
52-week range:
$39.41 - $91.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.79x
Volume:
3.1M
Avg. volume:
2M
1-year change:
-33.04%
Market cap:
$3.5B
Revenue:
$370M
EPS (TTM):
-$2.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
$7.1M | -$1.40 | -96.15% | -0.36% | $81.75 |
|
ACIU
AC Immune SA
|
$8.4M | -$0.22 | -96.14% | -284.28% | -- |
|
ADXN
Addex Therapeutics
|
$130K | -- | 2.35% | -- | -- |
|
LZAGY
Lonza Group
|
-- | -- | -- | -- | -- |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- |
|
VRTX
Vertex Pharmaceuticals
|
$2.7B | $4.13 | 10.59% | 10.32% | $498.24 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
$40.72 | $81.75 | $3.5B | -- | $0.00 | 0% | -- |
|
ACIU
AC Immune SA
|
$2.68 | -- | $265.2M | -- | $0.00 | 0% | -- |
|
ADXN
Addex Therapeutics
|
$7.90 | -- | $8.4M | -- | $0.00 | 0% | 14.60x |
|
LZAGY
Lonza Group
|
$59.34 | -- | $42.8B | 66.93x | $0.44 | 0.74% | 5.74x |
|
NLSP
NLS Pharmaceutics
|
$1.92 | -- | $7.3M | -- | $0.00 | 0% | -- |
|
VRTX
Vertex Pharmaceuticals
|
$397.27 | $498.24 | $102.3B | 25.59x | $0.00 | 0% | 9.73x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
-- | 2.848 | -- | -- |
|
ACIU
AC Immune SA
|
-- | 6.835 | -- | 1.82x |
|
ADXN
Addex Therapeutics
|
-- | 2.474 | -- | 4.36x |
|
LZAGY
Lonza Group
|
28.87% | 0.600 | 10.72% | 1.38x |
|
NLSP
NLS Pharmaceutics
|
-- | 3.440 | -- | -- |
|
VRTX
Vertex Pharmaceuticals
|
-- | 0.893 | -- | 2.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
-$11.2M | -$110.1M | -- | -- | -- | -$107.1M |
|
ACIU
AC Immune SA
|
-- | $8.4M | -28.55% | -28.55% | 21.72% | -$12.8M |
|
ADXN
Addex Therapeutics
|
-- | -$719.5K | 91.08% | 91.08% | -2836.3% | -$713.3K |
|
LZAGY
Lonza Group
|
-- | -- | 4.35% | 5.75% | -- | -- |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- | -- |
|
VRTX
Vertex Pharmaceuticals
|
$2.4B | $1.1B | -2.89% | -2.89% | 44.43% | $1.3B |
CRISPR Therapeutics AG vs. Competitors
-
Which has Higher Returns CRSP or ACIU?
AC Immune SA has a net margin of -- compared to CRISPR Therapeutics AG's net margin of 21.59%. CRISPR Therapeutics AG's return on equity of -- beat AC Immune SA's return on equity of -28.55%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-- -$1.01 -- ACIUAC Immune SA-- $0.06 $154.7M -
What do Analysts Say About CRSP or ACIU?
CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 100.76%. On the other hand AC Immune SA has an analysts' consensus of -- which suggests that it could grow by 282.29%. Given that AC Immune SA has higher upside potential than CRISPR Therapeutics AG, analysts believe AC Immune SA is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG11 11 2 ACIUAC Immune SA0 0 0 -
Is CRSP or ACIU More Risky?
CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.207%.
-
Which is a Better Dividend Stock CRSP or ACIU?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or ACIU?
CRISPR Therapeutics AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $29.5M. CRISPR Therapeutics AG's net income of -$85.9M is lower than AC Immune SA's net income of $6.4M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG-- -- -- -$85.9M ACIUAC Immune SA-- -- $29.5M $6.4M
-
Which has Higher Returns CRSP or ADXN?
Addex Therapeutics has a net margin of -- compared to CRISPR Therapeutics AG's net margin of -2841.85%. CRISPR Therapeutics AG's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-- -$1.01 -- ADXNAddex Therapeutics-- -$2.78 $13.1M -
What do Analysts Say About CRSP or ADXN?
CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 100.76%. On the other hand Addex Therapeutics has an analysts' consensus of -- which suggests that it could grow by 279.75%. Given that Addex Therapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe Addex Therapeutics is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG11 11 2 ADXNAddex Therapeutics0 0 0 -
Is CRSP or ADXN More Risky?
CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CRSP or ADXN?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or ADXN?
CRISPR Therapeutics AG quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. CRISPR Therapeutics AG's net income of -$85.9M is lower than Addex Therapeutics's net income of -$1.8M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 14.60x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG-- -- -- -$85.9M ADXNAddex Therapeutics14.60x -- $62.3K -$1.8M
-
Which has Higher Returns CRSP or LZAGY?
Lonza Group has a net margin of -- compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -- beat Lonza Group's return on equity of 5.75%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-- -$1.01 -- LZAGYLonza Group-- -- $14.7B -
What do Analysts Say About CRSP or LZAGY?
CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 100.76%. On the other hand Lonza Group has an analysts' consensus of -- which suggests that it could fall by --. Given that CRISPR Therapeutics AG has higher upside potential than Lonza Group, analysts believe CRISPR Therapeutics AG is more attractive than Lonza Group.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG11 11 2 LZAGYLonza Group0 0 0 -
Is CRSP or LZAGY More Risky?
CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison Lonza Group has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.968%.
-
Which is a Better Dividend Stock CRSP or LZAGY?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lonza Group offers a yield of 0.74% to investors and pays a quarterly dividend of $0.44 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Lonza Group pays out 40.21% of its earnings as a dividend. Lonza Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRSP or LZAGY?
CRISPR Therapeutics AG quarterly revenues are --, which are smaller than Lonza Group quarterly revenues of --. CRISPR Therapeutics AG's net income of -$85.9M is higher than Lonza Group's net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Lonza Group's PE ratio is 66.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 5.74x for Lonza Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG-- -- -- -$85.9M LZAGYLonza Group5.74x 66.93x -- --
-
Which has Higher Returns CRSP or NLSP?
NLS Pharmaceutics has a net margin of -- compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -- beat NLS Pharmaceutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-- -$1.01 -- NLSPNLS Pharmaceutics-- -- -- -
What do Analysts Say About CRSP or NLSP?
CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 100.76%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12400.65%. Given that NLS Pharmaceutics has higher upside potential than CRISPR Therapeutics AG, analysts believe NLS Pharmaceutics is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG11 11 2 NLSPNLS Pharmaceutics0 0 0 -
Is CRSP or NLSP More Risky?
CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CRSP or NLSP?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or NLSP?
CRISPR Therapeutics AG quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. CRISPR Therapeutics AG's net income of -$85.9M is higher than NLS Pharmaceutics's net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG-- -- -- -$85.9M NLSPNLS Pharmaceutics-- -- -- --
-
Which has Higher Returns CRSP or VRTX?
Vertex Pharmaceuticals has a net margin of -- compared to CRISPR Therapeutics AG's net margin of 37.71%. CRISPR Therapeutics AG's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-- -$1.01 -- VRTXVertex Pharmaceuticals85.84% $4.01 $15.6B -
What do Analysts Say About CRSP or VRTX?
CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 100.76%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.24 which suggests that it could grow by 25.42%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG11 11 2 VRTXVertex Pharmaceuticals17 12 2 -
Is CRSP or VRTX More Risky?
CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.
-
Which is a Better Dividend Stock CRSP or VRTX?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or VRTX?
CRISPR Therapeutics AG quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. CRISPR Therapeutics AG's net income of -$85.9M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 9.73x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG-- -- -- -$85.9M VRTXVertex Pharmaceuticals9.73x 25.59x $2.8B $1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
